CATALOGO DEI PRODOTTI DELLA RICERCA

CINGARLINI, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.211
EU - Europa 5.314
AS - Asia 3.498
SA - Sud America 484
Continente sconosciuto - Info sul continente non disponibili 157
AF - Africa 107
OC - Oceania 11
Totale 15.782
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.031
RU - Federazione Russa 1.974
SG - Singapore 1.198
CN - Cina 1.177
GB - Regno Unito 1.026
IT - Italia 709
BR - Brasile 379
SE - Svezia 325
DE - Germania 320
VN - Vietnam 289
IE - Irlanda 266
HK - Hong Kong 265
FR - Francia 237
FI - Finlandia 174
BD - Bangladesh 125
CA - Canada 102
KR - Corea 101
IN - India 70
TR - Turchia 55
JP - Giappone 52
NL - Olanda 49
UA - Ucraina 42
MX - Messico 37
ES - Italia 35
AR - Argentina 33
BE - Belgio 29
PL - Polonia 29
ID - Indonesia 27
NG - Nigeria 25
IQ - Iraq 24
AT - Austria 19
MA - Marocco 18
ZA - Sudafrica 17
CO - Colombia 15
IR - Iran 15
CL - Cile 14
PK - Pakistan 13
VE - Venezuela 13
AE - Emirati Arabi Uniti 12
EC - Ecuador 11
LT - Lituania 11
SA - Arabia Saudita 11
PH - Filippine 10
UZ - Uzbekistan 10
AU - Australia 9
ET - Etiopia 8
JM - Giamaica 8
LV - Lettonia 8
MY - Malesia 8
AZ - Azerbaigian 7
CH - Svizzera 7
EG - Egitto 7
JO - Giordania 7
PY - Paraguay 7
TN - Tunisia 7
CR - Costa Rica 6
GR - Grecia 6
DK - Danimarca 5
KE - Kenya 5
PE - Perù 5
RO - Romania 5
UY - Uruguay 5
BJ - Benin 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
EE - Estonia 4
HN - Honduras 4
NI - Nicaragua 4
SI - Slovenia 4
TG - Togo 4
TH - Thailandia 4
BS - Bahamas 3
GT - Guatemala 3
HR - Croazia 3
IL - Israele 3
KW - Kuwait 3
MK - Macedonia 3
PA - Panama 3
PR - Porto Rico 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AL - Albania 2
BY - Bielorussia 2
CM - Camerun 2
HU - Ungheria 2
KZ - Kazakistan 2
NO - Norvegia 2
NP - Nepal 2
PS - Palestinian Territory 2
PT - Portogallo 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
DM - Dominica 1
Totale 15.612
Salva come PNG Salva come JPEG
Città #
Southend 866
Ashburn 796
Moscow 736
Singapore 638
Chandler 614
Dallas 606
San Jose 513
Verona 269
Hong Kong 257
Dublin 256
Jacksonville 249
Beijing 234
Ann Arbor 214
Woodbridge 205
New York 174
Council Bluffs 166
Los Angeles 133
The Dalles 131
Houston 97
Ho Chi Minh City 96
Munich 84
Jinan 76
Lawrence 76
Princeton 76
Wilmington 75
Shenyang 70
Helsinki 68
São Paulo 64
Hanoi 63
Santa Clara 63
Tianjin 56
Milan 54
Nanjing 53
Orem 45
Tokyo 45
Buffalo 42
Hebei 40
Columbus 36
Changsha 35
Guangzhou 34
Haikou 34
Denver 32
London 32
Montreal 32
Redmond 32
Redondo Beach 31
Zhengzhou 31
Brussels 29
Seattle 28
Toronto 28
Abuja 25
Bologna 25
Chicago 25
Sindelfingen 24
Warsaw 24
Nanchang 23
Taiyuan 23
Hangzhou 22
Seoul 22
Turku 22
Brooklyn 21
Chennai 21
Rome 21
Ningbo 20
Taizhou 20
Atlanta 19
Lancaster 19
Paris 19
Phoenix 19
Redwood City 19
Amsterdam 18
Frankfurt am Main 18
San Francisco 18
Shanghai 17
Falkenstein 16
Mexico City 16
Jiaxing 15
Rio de Janeiro 15
Washington 15
Da Nang 14
Manchester 14
Stockholm 14
Boardman 13
Kent 13
Poplar 13
Dong Ket 12
Jakarta 12
Johannesburg 12
Las Vegas 12
Turin 12
Madrid 11
Barnet 10
Charlotte 10
Curitiba 10
Fuzhou 10
Mumbai 10
New Delhi 10
Norwalk 10
Tashkent 10
Brescia 9
Totale 9.536
Salva come PNG Salva come JPEG
Nome #
Somatostatin analogs for resectable pancreatic neuroendocrine tumors in high-risk surgical patients: Data from a single-center cohort 323
Anti PSMA immunotoxins activity against prostate cancer cell lines. 303
Whole-genome landscape of pancreatic neuroendocrine tumours 294
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 281
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 267
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 264
Preclinical studies of a new anti-psma (prostate specific membrane antigen) antibody for diagnosis and immunotargeting 261
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer 260
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 260
CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms 251
Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity? Results from a Single-Center Surgical Series 248
The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs): Time-trend and Outcome Analysis From 587 Consecutive Resections at a High-volume Institution. 247
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 244
3D-CT texture analysis of neuroendocrine pancreatic neoplasms 239
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 235
Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors 233
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 231
A prospective non-randomised single-center study comparing laparoscopic and robotic distal pancreatectomy 227
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 225
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 223
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 220
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 218
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 217
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 216
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 210
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 208
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 205
Dual-tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT scan and G1-G2 non-functioning pancreatic neuroendocrine tumors: A single-center retrospective evaluation of 124 non-metastatic resected cases 204
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 203
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 203
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 203
Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells 202
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 202
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 202
ESGAR 2016 Book of Abstracts 202
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 200
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 200
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 198
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 196
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 194
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 193
Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components 192
The development of PARP as a successful target for cancer therapy 192
Liver Tumor Burden in Pancreatic Neuroendocrine Tumors: CT Features and Texture Analysis in the Prediction of Tumor Grade and 18F-FDG Uptake 190
Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors 187
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 186
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 182
Imaging presentation of pancreatic neuroendocrine neoplasms 176
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 176
Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors: a retrospective analysis of 110 cases 174
Pathological complete response in a patient affected by multiple synchronous, breast and lung primary malignancies: a case report and review of the literature 173
Patterns of recurrence after resection for pancreatic neuroendocrine tumors: who, when, and where? 173
Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center 170
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 169
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 168
Histogram analysis of ADC maps: assessment of intra-tumoral heterogeneity and correlation with the biological behavior of pancreatic neuroendocrine neoplasms 167
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 166
Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants 166
Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms 164
Digital Subtraction of Magnetic Resonance Images Improves Detection and Characterization of Pancreatic Neuroendocrine Neoplasms 161
Solid non-functioning endocrine tumors of the pancreas: correlating computed tomography and pathology 160
Prognostic Stratification and Therapeutic Response Assessment in Liver and Pancreatic Tumors: the New Imaging 157
Clinical presentation, genotype-phenotype correlations, and outcome of pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome 157
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 153
Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience 151
Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors: Why Not? 144
Is Laparoscopic CME Right Hemicolectomy an Optimal Indication for NET of the Right Colon and Terminal Ileum? 144
Differentiation of pancreatic neuroendocrine tumor grade comparing 3D CT texture analysis and relative CT enhancement ratios 143
Profiling mTOR pathway in neuroendocrine tumors 140
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 138
Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives 136
Ultra-Mutation in IDH Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment 132
Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring 128
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 126
Glucagon-Producing Pancreatic Neuroendocrine Tumors (Glucagonomas) are Enriched in Aggressive Neoplasms with ARX and PDX1 Co-expression, DAXX/ATRX Mutations, and ALT (Alternative Lengthening of Telomeres) 124
Pancreatic Neuroendocrine Neoplasms: Clinical Value of Diffusion-Weighted Imaging 124
Normal Tissue Perfusion Changes During Everolimus Treatment: Preliminary Results from a Functional Vascular Study 119
Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups 111
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size 111
Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors 107
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine 102
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? 93
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET) 85
Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors 18
Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape 16
Author Correction: The evolutionary history of 2,658 cancers (Nature, (2020), 578, 7793, (122-128), 10.1038/s41586-019-1907-7) 10
Patterns of somatic structural variation in human cancer genomes 9
Totale 15.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.265
article - articoli 35.235
book - libri 0
conference - conferenze 13.849
curatela - curatele 0
other - altro 645
patent - brevetti 1.066
selected - selezionate 0
volume - volumi 470
Totale 102.530
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022447 0 0 0 70 37 17 14 44 23 18 53 171
2022/20231.625 96 211 148 287 108 429 38 88 173 9 25 13
2023/2024835 29 66 75 82 90 166 25 50 9 65 144 34
2024/20251.933 104 112 108 273 99 76 104 88 279 137 182 371
2025/20266.618 412 354 507 1.112 1.736 403 526 340 514 383 134 197
2026/20271.148 254 181 296 417 0 0 0 0 0 0 0 0
Totale 15.782